2021 Fiscal Year Final Research Report
Development of radiotherapy combined with a new diagnostic marker for body fluids that enables ultra-minimally invasiveness
| Project/Area Number |
19K17140
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52040:Radiological sciences-related
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | エクソソーム / バイオマーカー |
|---|
| Outline of Final Research Achievements |
Exosomes are present in body fluids such as blood. They exist in both normal cells and cancer cells, and attempts are being made to use as a tool for cancer diagnosis by detecting the difference in exosomes present in both.
We focused on tear fluid and hypothesized if they could be used as a diagnostic tool, they could be used as a minimally invasive cancer diagnostic tool.
In this study, we found that tear fluid could be used for cancer diagnosis and prognosis in breast cancer patients.
|
| Free Research Field |
放射線腫瘍学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究ではエクソソームに着目して涙液をがんの診断および予後予測におけるツールとして利用できる可能性を初めて示した。これまで血液などが主体であった診断手法が、広く涙液を用いることができれば、自宅でも簡便に施行可能なキットへの開発に結び付けることも可能になりうると考えられる。このことは検診受検率の上昇、がんの早期発見および診断治療、ひいてはがんにおける全体的な生存率向上に寄与できる可能性を秘めており、その社会的意義は高いと考える。
|
